Company overview
IROA Technologies provides stable isotope-labeled standards, including 5% and 95% U-13C yeast extracts, and the TruQuant Workflow for accurate metabolomics normalization and analysis. Their solutions enhance data accuracy, reproducibility, and comparability in mass spectrometry-based workflows for clinical, pharmaceutical, and academic research. Founded in 2010 in Ann Arbor, Michigan, they offer automated tools that correct ionization inefficiencies and instrument variances.
Iroa Technologies is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include metabolomics standards, stable isotope labeling, u-13c yeast extract, truquant workflow, mass spectrometry metabolomics.
Products and technologies associated with Iroa Technologies include Mass Spectrometry — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.iroatech.com
- Markets served
- United States & Americas
- Keywords
- metabolomics standards, stable isotope labeling, u-13c yeast extract, truquant workflow, mass spectrometry metabolomics
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What metabolomics standards does IROA Technologies offer?
- IROA provides unique 5% and 95% U-13C labeled yeast extracts as internal standards, along with stable isotope-resolved metabolomics (SIRM) tools for precise identification and quantitation.
- What is the TruQuant Workflow and its benefits?
- The TruQuant Workflow uses stable isotope-labeled internal standards and companion algorithms to normalize metabolomics data, minimizing technical variability, improving accuracy, and enabling data comparability across studies and platforms.
- In which research areas and geographies are IROA solutions used?
- IROA solutions are scalable and applied globally in clinical, pharmaceutical, and academic metabolomics research, including phenotype characterization and biomarker identification.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
